Julie Yang

Julie comes to TRV by way of a happily non-linear path through academic research, drug development, and investing. Before joining TRV, she worked on the investment teams at TCG Crossover, Leaps by Bayer, and Bain Capital Life Sciences, where she evaluated biotechnology opportunities through scientific, clinical, and commercial lenses in search of differentiated asset profiles. Earlier in her career, Julie was a scientist at Dicerna Pharmaceuticals, contributing to discovery and drug development programs in rare and cardiovascular diseases. She was a post-doctoral fellow at Harvard Medical School studying potential therapeutic pathways for HCV. She holds a PhD in Molecular Biology and Biochemistry from Weill Cornell Medical School, where she studied miRNA function and its translational applications, and an MBA from INSEAD. She’s excited to bring this mix of experiences to TRV’s mission of building companies that develop impactful medicines.

Outside of TRV, Julie enjoys wandering national park trails, getting lost in good science fiction, and experimenting with growing different varieties of tomatoes (with mixed but enthusiastic results). She’s always happy to explore new landscapes and cultures through travel—and to stay connected to her Taiwanese roots along the way.